Monte Rosa Therapeutics, Inc.

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
16.02 ^USD	-0.12%		-10.00%	+2.17%

Mar. 02	Monte Rosa Therapeutics Insider Sold Shares Worth $464,886, According to a Recent SEC Filing	MT
Feb. 24	Monte Rosa Therapeutics, Inc. Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients At Asco Genitourinary Cancers	CI

Top Midday Gainers

Published on 01/07/2026 at 02:45 pm EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Monte Rosa Therapeutics, Inc.

Mar. 02	Monte Rosa Therapeutics Insider Sold Shares Worth $464,886, According to a Recent SEC Filing	MT
Feb. 24	Monte Rosa Therapeutics, Inc. Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients At Asco Genitourinary Cancers	CI
Feb. 22	Certain Pre-funded Warrants of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026.	CI
Feb. 22	Certain Restricted Stock Units of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026.	CI
Feb. 22	Certain Options of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026.	CI
Feb. 22	Certain Common Stock of Monte Rosa Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-FEB-2026.	CI
Feb. 10	Monte Rosa Therapeutics, Inc. Announces Executive Changes, Effective April 3, 2026	CI
Jan. 09	Monte Rosa Therapeutics Prices $300 Million Public Offering	MT
Jan. 08	Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share	RE
Jan. 07	Monte Rosa Therapeutics Inc - Terminates Sales Agreement Prospectus - SEC Filing	RE
Jan. 07	Monte Rosa Therapeutics Announces $200 Million Proposed Public Offering	MT
Jan. 07	Monte Rosa Therapeutics announces proposed public offering of common stock and pre-funded warrants	RE
Jan. 07	Top Midday Gainers	MT
Jan. 07	Monte Rosa Therapeutics Drug Reduces Cardiovascular Inflammation Markers in Interim Phase 1 Data	MT
Jan. 07	Monte Rosa Therapeutics, Inc. Announces Positive Interim Phase 1 Data of Mrt-8102 Demonstrating Profound Crp Reductions in Elevated Cvd- Risk Subjects	CI

Chart Monte Rosa Therapeutics, Inc.

Duration

Period

GLUE: Dynamic Chart

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the bodyâ€™s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Employees

147

Sector

Biotechnology & Medical Research

More about the company